Fortrea Holdings (FTRE) closed at $21.96 on November 6, 2026, up 7.3% from the previous close, on volume of 1,839,392 shares (30-day average 1,892,459).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 28, 2026 | Call Spread Tied to Stock | 20-Nov-2622.5 : 25 C +28,000 Stock | 4,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Four undervalued healthcare stocks with the highest year-over-year CapEx growth
Seeking Alpha News (Thu, 5-Nov 8:00 AM ET)
Fortrea Reports Third Quarter 2026 Results
Globe Newswire (Thu, 29-Oct 6:30 AM ET)
Fortrea to Participate in Jefferies Global Healthcare Conference
Globe Newswire (Tue, 27-Oct 7:00 AM ET)
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Globe Newswire (Thu, 22-Oct 4:05 PM ET)
Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials
Globe Newswire (Mon, 19-Oct 4:05 PM ET)
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
Globe Newswire (Mon, 5-Oct 6:30 AM ET)
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 10-Sep 5:08 PM ET)
Fortrea to Participate in September Investor Conferences
Globe Newswire (Thu, 10-Sep 8:58 AM ET)
Globe Newswire (Wed, 2-Sep 7:00 AM ET)
Fortrea Boosts 2026 Guidance on Back of Strong Book-to-Bill and Adjusted Profit Metrics
Market Chameleon (Wed, 29-Jul 4:46 AM ET)
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
Fortrea Holdings trades on the NASDAQ stock market under the symbol FTRE.
As of November 6, 2026, FTRE stock price climbed to $21.96 with 1,839,392 million shares trading.
FTRE has a beta of 1.31, meaning it tends to be more sensitive to market movements. FTRE has a correlation of 0.05 to the broad based SPY ETF.
FTRE has a market cap of $2.12 billion. This is considered a Mid Cap stock.
Last quarter Fortrea Holdings reported $692 million in Revenue and $.28 earnings per share. This beat revenue expectation by $20 million and exceeded earnings estimates by $.06.
In the last 3 years, FTRE traded as high as $41.02 and as low as $3.97.
The top ETF exchange traded funds that FTRE belongs to (by Net Assets): IJR, VTI, IWM, VXF, VB.
FTRE has outperformed the market in the last year with a return of +99.3%, while the SPY ETF gained +10.8%. In the last 3 month period, FTRE beat the market returning +24.1%, while SPY returned -4.1%. However, in the most recent 2 weeks FTRE has underperformed the stock market by returning -7.1%, while SPY returned -3.2%.
FTRE support price is $19.49 and resistance is $21.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FTRE shares will trade within this expected range on the day.
